SIEN Sientra

Sientra to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Sientra to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

SANTA BARBARA, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the fourth quarter and full year of 2020 after the close of trading on Thursday, March 11, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are 844-464-3933 for domestic callers and 765-507-2612 for international callers. The conference ID is 3371629.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at . The webcast will be archived on the website following the completion of the call.  

About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company uniquely focused on plastic surgeons. The Company offers a suite of products designed to make a difference in patients' lives by enhancing their body image, growing their self-esteem, and restoring their confidence. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s Breast Products Segment includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*). The Company’s miraDry Segment, comprised of its miraDry® system, is approved for sale in over 56 international markets and is the only non-surgical, FDA-cleared device indicated for the permanent reduction of underarm sweat and hair and may also reduce odor.

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at .

(*) Data on file

Contact

Investor Relations

805-679-8885



EN
25/02/2021

Underlying

SIENSientra

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sientra

 PRESS RELEASE
Free
SIEN SIENTRA

Sientra Announces Completion and Winning Bidders of its Section 363 Sa...

Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction Tiger Aesthetics Medical, LLC is the successful bidder for certain assets used in Sientra’s breast reconstruction and augmentation business Nuance Intermediary, LLC is the successful bidder for substantially all of the assets used in Sientra’s BIOCORNEUM scar treatment business IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (“Sientra” or the “Company”) announced that, following the completion of its Section 363 sales auction, Tiger Aesthetics Medical, LLC (“Tiger”) has been declared t...

April 2, 2024 1 EN
 PRESS RELEASE
Free
SIEN SIENTRA

Sientra to Pursue Strategic Sale of its Business Through Voluntary Cha...

Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Company secures $22.5 million of new money in debtor-in-possession financing from existing lenders to support ongoing operations during the sale process IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing and commercializing safe and innovative solutions for the best aesthetic outcomes, announced that it filed for Chapter 11 protection in the United States Bankruptcy Court for the District of Delaware on F...

February 13, 2024 1 EN
 PRESS RELEASE
Free
SIEN SIENTRA

Sientra Reports Third Quarter Financial and Operational Results

Sientra Reports Third Quarter Financial and Operational Results IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its financial results for the third quarter that ended September 30, 2023. Third Quarter 2023 Financial and Business Highlights Net sales of $19.5 million representing a decrease of 13.7% over the third quarter of 2022. For the first nine months of 2023, net sales totaled $65.2 million, a...

November 9, 2023 1 EN
 PRESS RELEASE
Free
SIEN SIENTRA

Sientra to Present at the Stifel 2023 Healthcare Conference

Sientra to Present at the Stifel 2023 Healthcare Conference IRVINE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company developing the safest and most innovative solutions for the best aesthetic outcomes, today announced its participation at the Stifel 2023 Healthcare Conference. As part of the conference, the company’s management team will participate in a live fireside chat on Wednesday, November 15, 2023 at 8:00am EST / 5:00am PST. An on-demand webcast of the presentation will be accessible under “News & Ev...

November 8, 2023 1 EN
 PRESS RELEASE
Free
SIEN SIENTRA

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Res...

Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook IRVINE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a surgical aesthetics company delivering the safest and most innovative solutions for the best outcomes, today announced preliminary unaudited financial results for the fiscal third quarter ended September 30, 2023. Total unaudited revenue for the third quarter of 2023 is expected to be in the range of $19.2 million to $19.7 million, compared to total revenue of $22.6 million ...

October 30, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch